UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial

Diabetes, obesity & metabolism, 2011-10, Vol.13 (10), p.928-938

2011

Volltextzugriff (PDF)

Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical Centre

Journal of Crohn's and colitis, 2020-07, Vol.14 (7), p.915-919

2020

Volltextzugriff (PDF)

A switch from originator-adalimumab to the biosimilar SB5 in patients with Crohn's disease: an analysis of two propensity score-matched cohorts

Scandinavian journal of gastroenterology, 2022-07, Vol.57 (7), p.814-824

2022

Volltextzugriff (PDF)

Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre

Digestive diseases (Basel), 2017-01, Vol.35 (1-2), p.91-100

2017

Volltextzugriff (PDF)

Twice-daily dapagliflozin co-administered with metformin in type 2 diabetes: a 16-week randomized, placebo-controlled clinical trial

Diabetes, obesity & metabolism, 2015-01, Vol.17 (1), p.42-51

2015

Volltextzugriff (PDF)

Advances in noise-based testing of concurrent software

Software testing, verification & reliability, 2015-05, Vol.25 (3), p.272-309

2015

Volltextzugriff (PDF)

P408 Dual therapy with vedolizumab and tofacitinib in refractory ulcerative colitis patients – single centre experience

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i538-i538

2023

Volltextzugriff (PDF)

P368 Tofacitinib induction efficiency and intracellular cytokine dynamics in ulcerative colitis: Results from clinical practice

Journal of Crohn's and colitis, 2020-01, Vol.14 (Supplement_1), p.S348-S348

2020

Volltextzugriff (PDF)

P373 Telemedicine and inflammatory bowel disease: Results of the IBD assistant pilot project

Journal of Crohn's and colitis, 2020-01, Vol.14 (Supplement_1), p.S352-S353

2020

Volltextzugriff (PDF)

P614 Pregnancy outcomes in women with IBD treated with biosimilar infliximab

Journal of Crohn's and colitis, 2018-01, Vol.12 (supplement_1), p.S419-S420

2018

Volltextzugriff (PDF)

P532 Biosimilar infliximab in anti-TNF naive inflammatory bowel disease patients – one-year clinical follow-up

Journal of Crohn's and colitis, 2017-02, Vol.11 (suppl_1), p.S350-S351

2017

Volltextzugriff (PDF)

P641 Ustekinumab efficiency as a higher-line therapy in association with serum levels in patients with Crohn’s disease

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S438-S439

2019

Volltextzugriff (PDF)

P487 Early vedolizumab trough levels are not associated with a short-term response in patients with inflammatory bowel disease

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S355-S356

2019

Volltextzugriff (PDF)

Effekt von Dapagliflozin bei Typ-2-Diabetikern mit unzureichender Blutzuckereinstellung unter Glimepirid

Deutsche medizinische Wochenschrift, 2013-04, Vol.138 (S 01), p.S16-S27

2013

Volltextzugriff (PDF)

P460 Impact of anti-TNFα exposure during pregnancy for maternal inflammatory bowel disease on serologic response to vaccination of exposed children

Journal of Crohn's and colitis, 2018-01, Vol.12 (supplement_1), p.S337-S337

2018

Volltextzugriff (PDF)

P734 Anti-TNFa exposure during pregnancy is not associated with increased infection risk in exposed children during the first year of life

Journal of Crohn's and colitis, 2018-01, Vol.12 (supplement_1), p.S482-S483

2018

Volltextzugriff (PDF)

Höhere Wirksamkeit von Dapagliflozin bei Patienten in höheren Baseline-HbA1c-Kategorien

Diabetologie und Stoffwechsel, 2013, Vol.8 (S 01)

2013

Volltextzugriff (PDF)

Pregnancy outcomes in women with inflammatory bowel disease treated with biosimilar infliximab

Gastroenterologie a hepatologie, 2018-02, Vol.72 (1), p.20-26

2018

Volltextzugriff (PDF)

Vedolizumab vs. ustekinumab as second-line therapy in Crohn’s disease in clinical practice

Gastroenterologie a hepatologie, 2019-02, Vol.73 (1), p.25-31

2019

Volltextzugriff (PDF)

Early vedolizumab trough levels are not associated with short-term response in patients with inflammatory bowel disease

Gastroenterologie a hepatologie, 2019-02, Vol.73 (1), p.32-36

2019

Volltextzugriff (PDF)

Biosimilar infliximab in anti-TNF-naïve IBD patients – 1-year clinical follow-up

Gastroenterologie a hepatologie, 2016-12, Vol.70 (6), p.514-522

2016

Volltextzugriff (PDF)

Dapagliflozin, ein selektiver SGLT-2 Hemmer, hat eine geringe Neigung Hypoglykämien zu verursachen bei Patienten mit Type 2 Diabetes

Diabetologie und Stoffwechsel, 2012-05, Vol.7 (S 01)

2012

Volltextzugriff (PDF)

Tofacitinib induction efficacy and safety in ulcerative colitis at week 8 – results from clinical practice

Gastroenterologie a hepatologie, 2020-02, Vol.74 (1), p.28-34

2020

Volltextzugriff (PDF)

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride

Deutsche medizinische Wochenschrift (1946), 2013-04, Vol.138 Suppl 1, p.S16

2013

Volltextzugriff (PDF)

Induction of tolerance to skin graft by previous immunization with an isolated antibody against tissue antigens of a skin graft donor. (Preliminary communication)

Sbornik vedeckych praci Lekarske fakulty Karlovy university v Hradci Kralove, 1969, Vol.12 (5), p.537

1969

Volltextzugriff (PDF)

1 – 25 von 119

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(98)
Mit Volltextzugriff
(54)

Publikationsform

Artikel
(118)
Tagungsberichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial

Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical Centre

A switch from originator-adalimumab to the biosimilar SB5 in patients with Crohn's disease: an analysis of two propensity score-matched cohorts

Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre

Twice-daily dapagliflozin co-administered with metformin in type 2 diabetes: a 16-week randomized, placebo-controlled clinical trial

Advances in noise-based testing of concurrent software

P408 Dual therapy with vedolizumab and tofacitinib in refractory ulcerative colitis patients – single centre experience

P368 Tofacitinib induction efficiency and intracellular cytokine dynamics in ulcerative colitis: Results from clinical practice

P373 Telemedicine and inflammatory bowel disease: Results of the IBD assistant pilot project

P614 Pregnancy outcomes in women with IBD treated with biosimilar infliximab

P532 Biosimilar infliximab in anti-TNF naive inflammatory bowel disease patients – one-year clinical follow-up

P641 Ustekinumab efficiency as a higher-line therapy in association with serum levels in patients with Crohn’s disease

P487 Early vedolizumab trough levels are not associated with a short-term response in patients with inflammatory bowel disease

Effekt von Dapagliflozin bei Typ-2-Diabetikern mit unzureichender Blutzuckereinstellung unter Glimepirid

P460 Impact of anti-TNFα exposure during pregnancy for maternal inflammatory bowel disease on serologic response to vaccination of exposed children

P734 Anti-TNFa exposure during pregnancy is not associated with increased infection risk in exposed children during the first year of life

Höhere Wirksamkeit von Dapagliflozin bei Patienten in höheren Baseline-HbA1c-Kategorien

Pregnancy outcomes in women with inflammatory bowel disease treated with biosimilar infliximab

Vedolizumab vs. ustekinumab as second-line therapy in Crohn’s disease in clinical practice

Early vedolizumab trough levels are not associated with short-term response in patients with inflammatory bowel disease

Biosimilar infliximab in anti-TNF-naïve IBD patients – 1-year clinical follow-up

Dapagliflozin, ein selektiver SGLT-2 Hemmer, hat eine geringe Neigung Hypoglykämien zu verursachen bei Patienten mit Type 2 Diabetes

Tofacitinib induction efficacy and safety in ulcerative colitis at week 8 – results from clinical practice

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride

Induction of tolerance to skin graft by previous immunization with an isolated antibody against tissue antigens of a skin graft donor. (Preliminary communication)

Suchergebnisse filtern